<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00272662</url>
  </required_header>
  <id_info>
    <org_study_id>AFX01-05</org_study_id>
    <secondary_id>2005-003354-10</secondary_id>
    <nct_id>NCT00272662</nct_id>
  </id_info>
  <brief_title>Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affymax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affymax</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and&#xD;
      pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in&#xD;
      anemic cancer participants receiving chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2, open-label, multi-center, sequential dose finding study with up to 6&#xD;
      treatment cohorts receiving chemotherapy with 15 participants per cohort. The primary&#xD;
      objective of this study was to determine the dose of peginesatide administered every 3 weeks&#xD;
      (Q3W) by subcutaneous injection associated with a hemoglobin increase of ≥ 1 g/dL in ≥ 50% of&#xD;
      anemic cancer participants receiving chemotherapy at 9 weeks following the first dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with a hemoglobin increase of ≥ 1 gram per deciliter (g/dL) at 9 weeks following Dose 1</measure>
    <time_frame>Week 9 post Dose 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>13 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve hemoglobin increase ≥ 1 g/dL from baseline</measure>
    <time_frame>Baseline to Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a hemoglobin response</measure>
    <time_frame>13 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>13 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chemotherapy Induced Anemia</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.1 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 3 weeks (Q3W) for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.15 mg/kg administered SC Q3W for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.2 mg/kg administered SC Q3W for a total of 4 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginesatide starting dose of 0.05 mg/kg administered SC Q3W for a total of 4 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginesatide</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Omontys</other_name>
    <other_name>Hematide</other_name>
    <other_name>AF37702 Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is informed of the investigational nature of this study and has given&#xD;
             written, witnessed informed consent in accordance with institutional, local, and&#xD;
             national guidelines&#xD;
&#xD;
          -  Males or females ≥ 18 and ≤ 80 years of age; pre-menopausal females (with the&#xD;
             exception of those who are surgically sterile) must have a negative pregnancy test at&#xD;
             screening; those who are sexually active must practice a highly effective method of&#xD;
             birth control for at least 2 weeks prior to study start, and must be willing to&#xD;
             continue practicing birth control for at least 4 weeks after the last dose of study&#xD;
             drug. A highly effective method of birth control is defined as one that results in a&#xD;
             low failure rate (i.e., less than 1% per year) when used consistently and correctly&#xD;
             such as implants, injectables, combined oral contraceptives, some IUDs, sexual&#xD;
             abstinence (only acceptable if practiced as a life-style and not acceptable if one who&#xD;
             is sexually active practices abstinence only for the duration of study) or&#xD;
             vasectomized partner&#xD;
&#xD;
          -  Participants with histologically confirmed solid tumor malignancy or lymphoma who are&#xD;
             scheduled to receive at least 9 weeks of cyclic myelosuppressive chemotherapy while on&#xD;
             study&#xD;
&#xD;
          -  Hemoglobin value of ≥ 8 and &lt; 11 g/dL within 1 week prior to administration of study&#xD;
             drug.&#xD;
&#xD;
          -  ECOG Performance Status of 0-2&#xD;
&#xD;
          -  One reticulocyte hemoglobin content (CHr) &gt; 29 picograms within 4 weeks prior to study&#xD;
             drug administration.&#xD;
&#xD;
          -  One transferrin saturation ≥ 15% within 4 weeks prior to study drug administration.&#xD;
&#xD;
          -  One serum or red cell folate level above the lower limit of normal within 4 weeks&#xD;
             prior to study drug administration&#xD;
&#xD;
          -  One vitamin B12 level above the lower limit of normal within 4 weeks prior to study&#xD;
             drug administration&#xD;
&#xD;
          -  One absolute neutrophil count ≥ 1.0 x 10^9/L within 1 week prior to administration of&#xD;
             study drug&#xD;
&#xD;
          -  One platelet count ≥ 75 x 10^9/L within 1 week prior to administration of study drug&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any erythropoiesis stimulating agent (ESA) in the past 90 days&#xD;
&#xD;
          -  History of failure to respond to ESA treatment&#xD;
&#xD;
          -  Known antibodies to other ESAs or history of pure red cell aplasia (PRCA)&#xD;
&#xD;
          -  Acute or chronic leukemia, myelodysplastic syndrome (MDS), or multiple myeloma&#xD;
&#xD;
          -  Any previous or planned radiotherapy to more than 50% of either the pelvis or spine&#xD;
&#xD;
          -  Known intolerance to parenteral iron supplementation&#xD;
&#xD;
          -  Red blood cell transfusion within 4 weeks prior to study drug administration&#xD;
&#xD;
          -  Known hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all&#xD;
             types, etc.)&#xD;
&#xD;
          -  Known hemolysis&#xD;
&#xD;
          -  History of pulmonary embolism or deep venous thrombosis (DVT) in the previous 2 years&#xD;
             or current therapeutic doses of anticoagulants&#xD;
&#xD;
          -  Known blood loss as a cause of anemia&#xD;
&#xD;
          -  Uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid arthritis,&#xD;
             systemic lupus erythematosus, etc.)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2.5 times the&#xD;
             upper limit of normal; AST or ALT &gt; 5 times the upper limit of normal if liver&#xD;
             metastases are present.&#xD;
&#xD;
          -  Creatinine &gt; 175 micromoles per liter (µmol/L)&#xD;
&#xD;
          -  History of bone marrow or peripheral blood cell transplantation&#xD;
&#xD;
          -  Pyrexia/fever of ≥ 39 °C within 48 hours prior to study drug administration&#xD;
&#xD;
          -  Poorly controlled hypertension, per the Investigator's judgment, within 4 weeks prior&#xD;
             to study drug administration (e.g., systolic ≥ 170 mm Hg or diastolic ≥ 100 mm Hg on&#xD;
             repeat readings)&#xD;
&#xD;
          -  Epileptic seizure in the 6 months prior to study drug administration&#xD;
&#xD;
          -  Advanced chronic congestive heart failure - New York Heart Association Class IV&#xD;
&#xD;
          -  High likelihood of early withdrawal or interruption of the study&#xD;
&#xD;
          -  Anticipated elective surgery during the study period&#xD;
&#xD;
          -  History of multiple drug allergies&#xD;
&#xD;
          -  Exposure to any investigational agent within 1 month prior to administration of study&#xD;
             drug or planned receipt during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Affymax</last_name>
    <role>Study Director</role>
    <affiliation>Affymax, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facilities</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Pribram</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facilities</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facilities</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>January 5, 2006</study_first_submitted>
  <study_first_submitted_qc>January 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>chemotherapy induced anemia</keyword>
  <keyword>CIA</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>Hb</keyword>
  <keyword>Hgb</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>EPO</keyword>
  <keyword>erythropoiesis stimulating agent</keyword>
  <keyword>ESA</keyword>
  <keyword>Hematide</keyword>
  <keyword>Omontys</keyword>
  <keyword>peginesatide</keyword>
  <keyword>red blood cell</keyword>
  <keyword>red blood cell production</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

